SAN FRANCISCO--(BUSINESS WIRE)--Sequenta, Inc. and the Eastern Cooperative Oncology Group (now part of the ECOG-ACRIN Cancer Research Group) today announced an agreement to use Sequenta’s LymphoSIGHT™ next-generation sequencing method for the measurement of minimal residual disease (MRD) in a prospective clinical trial.
